Clinical Trial Update: Pazopanib as Single Agent in Advanced NETs [Phase 2]

View source ↗

Summary

Phase 2 trial of pazopanib as a single agent in advanced/metastatic neuroendocrine tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Neuroendocrine Tumors

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Advanced/Metastatic Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2019-03-04